FOLH1 and hereditary clear cell renal cell carcinoma: Additional 2-[18F]FDG PET/CT is a useful adjunct for theragnostic assessment for PSMA-radioligand therapy, and combined FDG/PSMA PET might be useful in renal cell carcinoma [99].